YZi Labs, backed by Changpeng Zhao, sharply criticized the management of Nasdaq-listed CEA Industries, claiming that it was taking steps to protect the current administration while undermining shareholder rights. Through a post made on Wednesday, YZi Labs stated that CEA’s use of the “poison pill” defense mechanism and amendments to its articles of association are preventing shareholders from acting through written consent. The situation, which began with a promising partnership five months ago, has evolved into an open power struggle over control of the board. At the center of the debate is the misalignment between CEA’s strategic direction and company performance.
Background of the Boardroom Struggle
The tension escalated when YZi Labs initiated aggressive efforts last month to alter the board structure of CEA Industries. The investment company demanded the expansion of the board, the reversal of recent amendments to the articles of association, and the appointment of its slate of candidates through written consent. These steps clearly indicate YZi Labs’ aim to wield more direct influence over the company.
Additionally, YZi Labs officially applied to form a coordinated group of shareholders, expressing its intent to increase its stake in the company. Following a $500 million private equity investment completed in July, the company maintained that CEA’s performance remained lackluster. They argued that the firm’s fundamental strategy was not progressing in alignment with its balance sheet asset, BNB, despite a strong price surge of an alternative altcoin during the same period.
YZi representatives claim that despite this scenario, the management has failed to chart a course that aligns with investor expectations, making management changes imperative.
The Poison Pill and Shareholder Reaction
In response to YZi Labs’ maneuvers, CEA Industries’ board adopted a short-term shareholder rights plan. This “poison pill” mechanism activates if any individual or group acquires 15% or more of the company’s shares without board approval. It allows other shareholders to purchase new shares at a 50% discount, significantly increasing the cost of a rapid takeover.
YZi Labs criticized these arrangements as unfriendly to shareholders. They claimed the new articles of association provisions effectively rendered the written consent process non-functional and restricted investor autonomy. Additionally, concerns arose among shareholders investing in BNB due to CEA CEO David Namdar indicating a potential shift towards other altcoins such as Solana.
